Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — Shareholder Meeting (April 2021)
36 slides from Hyphens Pharma International's shareholder meeting presentation, Apr 28, 2021
Slide 1: Hyphens Pharma International Limited 3rd Annual General Meeting
HYPHENS PHARMA INTERNATIONAL LIMITED 3RD ANNUAL GENERAL MEETING 28 APRIL 2021
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 3: Corporate Presentation
ORPOR A D>)» f\ @ Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 4: Our Strategic Focus
OUR STRATEGIC FOCUS ASEAN’s Leading Long-Term Goal Pharmaceuticals & Asia’s No. 1 Consumer Healthcare Skin Health Group Company
Slide 5: Our Business Segments
OUR BUSINESS SEGMENTS 1 Specialty Pharma Principals Ceradan TDF 2 Proprietary Brands CG 210 Ocean Health 3 Medical Hypermart and Digital
Slide 6: Annual Report 2020
ANNUAL REPORT 2020 Deepening Digital Capabilities Expanding Regionally Widening Product Portfolio Creating Value via Intangible Assets Supporting Community Outreach Financial Performance Rewarding Shareholders
Slide 7: Deepening Digitalisation Capabilities
1 DEEPENING DIGITALISATION CAPABILITIES 8:51 Building the Digital Transformation Talent Pool are available in Senior Manager, Digital Transformation E-Commerce & Digital Services Manager Shopee Lazada Qoo10 Amazon Associate E-Commerce Manager
Slide 8: Expanding Regionally
2 EXPANDING REGIONALLY JSPharma Shanghai Good Luck 上海古腊国际 South Korea 贸易有限公司 Mainland China Healthguard SUTL HK Pharmacy Limited Hong Kong, Macau and Duty-Free Sri Lanka Channels in China
Slide 9: Widening Product Portfolio
3 WIDENING PRODUCT PORTFOLIO Hyphens has acquired the rights, titles and interests in the trademarks of CG 210® for Singapore & Malaysia CG 210® is a globally renowned & patented topical botanical hair growth-promoting agent New brand ownership adds to our Proprietary Brands business segment
Slide 10: Widening Product Portfolio
3 WIDENING PRODUCT PORTFOLIO Patent for Ceradan® Advanced technology in UK. Patent pending in 13 other countries/ region. New product launches: + Ceradan® facelift:
Slide 11: Widening Product Portfolio
3 WIDENING PRODUCT PORTFOLIO NEW
Slide 12: Creating Value via Intangible Assets
4 CREATING VALUE VIA INTANGIBLE ASSETS
Slide 13: Supporting Community Outreach
5 SUPPORTING COMMUNITY OUTREACH to give back to our communities
Slide 14: Financial Performance
6.1 FINANCIAL PERFORMANCE Revenue (S$’m) Profit After Tax (S$’m) 6.5 120.9 6.1 6.2 112.7 119.4 123.7 101 5.4 5.2
Slide 15: Revenue by Business Segments
6.2 REVENUE BY BUSINESS SEGMENTS 140.0 120.0 100.0 Revenue S$’mil 57% 55% 52% 80.0 60.0 11% 12% 15% 40.0 20.0 32% 33% 33% 0.0 FY2018 FY2019 FY2020 Specialty 69.4 65.1 64.6 Proprietary 13.2 14.5 18.2 Hypermart 38.3 39.8 40.9 Total 120.9 119.4 123.7
Slide 16: EBITDA by Business Segments
6.3 EBITDA BY BUSINESS SEGMENTS 12.0 9.0 10.1 9.3 10.0 8.0 EBITDA S$’mil 6.2 Specialty 6.0 7.2 6.1 Proprietary 4.0 Hypermart 1.0 Unallocated 2.0 0.9 2.2 3.4 1.9 1.1 0.0 FY2018 FY2019 FY2020 -2.0 EBITDA margin Specialty 10.4% 9.5% 9.4% Proprietary 6.8% 6.9% 12.1% Hypermart 5.0% 8.5% 2.7%
Slide 17: Rewarding Shareholders
7 REWARDING SHAREHOLDERS S$’000 Dividend Yield(a) Div / NP(b) FY2020 0.62 cents 1.9% 30.2% (subj to shareholders’ approval) FY2019 1 cent 3.1% 46.0% FY2018 0.55 cents 1.7% 30.5% (a) Yield is computed based on total dividends declared for the financial year divided by closing price of S$0.32 @ 23 Apr
Slide 18: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 19: Investing for Growth
INVESTING FOR GROWTH 1. Investment in Proprietary Brands 2. Internationalisation 3. Going Digital 4. Strengthen Specialty Pharma portfolio 5. Acquisitions 6. Challenges – COVID-19
Slide 20: Questions & Answers
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 21: Questions from Shareholders
QUESTIONS FROM SHAREHOLDERS Q1: For the past 3 years, Group revenue is stagnant at around S$120 million and profit net of tax is also stagnant at around S$6 million. Is the Company concerned with this stagnation? Where is the growth going to come from, both top line and bottom line? Q2: Hyphens mark
Slide 22: Questions from Shareholders
QUESTIONS FROM SHAREHOLDERS Q3: Although the China market holds enormous opportunities, it is also very competitive. As such, can the management please share the China expansion/ marketing strategy for Ceradan? Where/How is Ceradan sold in China? Q4: Why did Hyphens only market TDF Fairence in the S
Slide 23: Questions from Shareholders
QUESTIONS FROM SHAREHOLDERS Q6: Why did revenue of Medical Hypermart & Digital segment increase from S$39.8 million to S$40.8 million yet EBITDA declined from S$3.4 million to S$1.1 million? Did you face more competition that necessitated a reduction in your margins? Q7: Hyphens had signed a memoran
Slide 24: Resolutions
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 25: Resolution 1
RESOLUTION 1 To receive and adopt the Directors’ Statement and Audited Financial Statements of the Company for the financial year ended 31 December 2020 together with the Auditors’ Report thereon. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 241,290,256 100 -
Slide 26: Resolution 2
RESOLUTION 2 To declare a final tax exempt (one-tier) dividend of 0.62 Singapore cents per ordinary share for the financial year ended 31 December 2020. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 241,290,256 100 - - -
Slide 27: Resolution 3
RESOLUTION 3 To re-elect Mr Heng Wee Koon under Regulation 97 of the Constitution. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 234,669,056 97.26 6,621,200 2.74 -
Slide 28: Resolution 4
RESOLUTION 4 To re-elect Mr Ng Eng Leng under Regulation 97 of the Constitution. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 234,669,056 97.26 6,621,200 2.74 -
Slide 29: Resolution 5
RESOLUTION 5 To re-elect Mr Chan Kiat under Regulation 103 of the Constitution. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 241,290,256 100 - - -
Slide 30: Resolution 6
RESOLUTION 6 To approve the Directors’ fees of SGD 184,900 for the year ended 31 December 2020. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 126,863,895 100 - - 114,426,361
Slide 31: Resolution 7
RESOLUTION 7 To re-appoint RSM Chio Lim LLP as auditors of the Company and to authorise the Directors to fix their remuneration. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 234,669,056 97.26 6,621,200 2.74 -
Slide 32: Resolution 8
RESOLUTION 8 To authorise Directors to allot and issue new shares pursuant to Section 161 of the Companies Act (Chapter 50) and Rule 806 of the SGX-ST Listing Manual Section B: Rule of Catalist. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 234,622,900 97.24 6
Slide 33: Resolution 9
RESOLUTION 9 To authorise Directors to grant awards and issue shares in accordance with Hyphens Performance Share Plan. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 120,127,339 94.75 6,657,356 5.25 114,505,561
Slide 34: Resolution 10
RESOLUTION 10 To authorise Directors to grant options and issue shares in accordance with Hyphens Share Option Scheme. Votes in Favour Votes Against Abstained No. of shares % No. of shares % No. of shares 120,127,339 94.75 6,657,356 5.25 114,505,561
Slide 35: Scrutineer's Certificate
7] goss SCRUTINEER’S CERTIFICATE = .2#E0S2.SS, em ‘www drewnspier com drewcorp 26 April 2021 To: The Board of Directors Hyphens Pharma Intemational Limited (Issuer) Dear Sirs, ‘As scrutineer appointed for the poll conducted at the Annual General Meeting of the Issuer held by way of electronic means
Slide 36: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — Shareholder Meeting (April 2021) on 6ix